Thermo Fisher Scientific Named Key Player Across Five High-Growth Genomics and Biotech Market Reports

Thermo Fisher Scientific figures prominently in a cluster of newly published market research reports covering fast-expanding segments of genomics, gene therapy, and AI-driven drug discovery. The reports, released on November 9, 2026, collectively highlight the company as a leading competitor across DNA profiling, CRISPR screening, genome annotation, gene therapy quality control, and AI-powered genomic variant prioritization.

The DNA Profiling Kits market, where Thermo Fisher competes alongside Illumina, QIAGEN, and Promega, is forecast to grow at a 12.2% compound annual growth rate through 2030, driven by adoption of next-generation sequencing, artificial intelligence, and laboratory automation. The Arrayed CRISPR Screening market, in which Thermo Fisher joins Merck, Agilent, and GenScript, is projected to reach $3.43 billion, expanding at a 17.7% CAGR as the technology accelerates precision drug discovery.

Two additional reports underscore Thermo Fisher's positioning in gene therapy infrastructure and AI diagnostics. The Release Testing for Gene Therapy market is expected to grow at a 16.5% CAGR through 2030, with Thermo Fisher, Lonza, Eurofins, and WuXi AppTec cited as leaders in automated quality control. The Genomic Variant Prioritization AI market carries the steepest growth projection of the group, a 26.5% CAGR, with Thermo Fisher named alongside Illumina, QIAGEN, and Tempus AI as key participants shaping that segment.